Business Description
Lexaria Bioscience Corp
NAICS : 325412
SIC : 2834
ISIN : US52886N3070
Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 47.85 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.07 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.2 | |||||
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | 23.4 | |||||
| 3-Year Book Growth Rate | -39.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -21.21 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 98.08 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.87 | |||||
| 9-Day RSI | 44.76 | |||||
| 14-Day RSI | 45.57 | |||||
| 3-1 Month Momentum % | -34.11 | |||||
| 6-1 Month Momentum % | -31.31 | |||||
| 12-1 Month Momentum % | 58.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.19 | |||||
| Quick Ratio | 7.19 | |||||
| Cash Ratio | 5.97 | |||||
| Days Sales Outstanding | 38.55 | |||||
| Days Payable | 22542.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.3 | |||||
| Shareholder Yield % | -10.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.92 | |||||
| Operating Margin % | -1239.87 | |||||
| Net Margin % | -1249.14 | |||||
| FCF Margin % | -1109.7 | |||||
| ROE % | -92.1 | |||||
| ROA % | -90.71 | |||||
| ROIC % | -410.87 | |||||
| 3-Year ROIIC % | 40.49 | |||||
| ROC (Joel Greenblatt) % | -986.59 | |||||
| ROCE % | -94.94 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 54.63 | |||||
| PB Ratio | 4.41 | |||||
| Price-to-Tangible-Book | 4.71 | |||||
| EV-to-EBIT | -5.69 | |||||
| EV-to-Forward-EBIT | -1.27 | |||||
| EV-to-EBITDA | -5.78 | |||||
| EV-to-Revenue | 70.42 | |||||
| EV-to-Forward-Revenue | 59.63 | |||||
| EV-to-FCF | -6.35 | |||||
| Price-to-GF-Value | 1.19 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 4.98 | |||||
| Price-to-Net-Cash | 6.22 | |||||
| Earnings Yield (Greenblatt) % | -17.57 | |||||
| FCF Yield % | -13.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LEXX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexaria Bioscience Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.464 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 0.81 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 155.92 | ||
| 14-Day RSI | 45.57 | ||
| 14-Day ATR ($) | 0.227337 | ||
| 20-Day SMA ($) | 2.257 | ||
| 12-1 Month Momentum % | 58.04 | ||
| 52-Week Range ($) | 1.2 - 6.85 | ||
| Shares Outstanding (Mil) | 17.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexaria Bioscience Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexaria Bioscience Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lexaria Bioscience Corp Frequently Asked Questions
What is Lexaria Bioscience Corp(LEXX)'s stock price today?
The current price of LEXX is $2.24. The 52 week high of LEXX is $6.85 and 52 week low is $1.20.
When is next earnings date of Lexaria Bioscience Corp(LEXX)?
The next earnings date of Lexaria Bioscience Corp(LEXX) is 2025-01-10 Est..
Does Lexaria Bioscience Corp(LEXX) pay dividends? If so, how much?
Lexaria Bioscience Corp(LEXX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers